DE60328777D1 - Ester in position 20 von camptothecinen - Google Patents

Ester in position 20 von camptothecinen

Info

Publication number
DE60328777D1
DE60328777D1 DE60328777T DE60328777T DE60328777D1 DE 60328777 D1 DE60328777 D1 DE 60328777D1 DE 60328777 T DE60328777 T DE 60328777T DE 60328777 T DE60328777 T DE 60328777T DE 60328777 D1 DE60328777 D1 DE 60328777D1
Authority
DE
Germany
Prior art keywords
camptothecinen
von
ester
von camptothecinen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328777T
Other languages
German (de)
English (en)
Inventor
Mauro Marzi
Domenico Alloatti
Claudio Pisano
Maria Ornella Tinti
Loredana Vesci
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Application granted granted Critical
Publication of DE60328777D1 publication Critical patent/DE60328777D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DE60328777T 2002-05-31 2003-05-28 Ester in position 20 von camptothecinen Expired - Lifetime DE60328777D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000306A ITRM20020306A1 (it) 2002-05-31 2002-05-31 Esteri in posizione 20 di camptotecine.
PCT/IT2003/000329 WO2003101996A2 (en) 2002-05-31 2003-05-28 Esters in position 20 of camptothecins

Publications (1)

Publication Number Publication Date
DE60328777D1 true DE60328777D1 (en) 2009-09-24

Family

ID=11456339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328777T Expired - Lifetime DE60328777D1 (en) 2002-05-31 2003-05-28 Ester in position 20 von camptothecinen

Country Status (21)

Country Link
US (2) US7452900B2 (enExample)
EP (2) EP1509529B1 (enExample)
JP (1) JP4593270B2 (enExample)
KR (1) KR101000963B1 (enExample)
CN (1) CN100376583C (enExample)
AR (1) AR040140A1 (enExample)
AT (1) ATE439362T1 (enExample)
AU (1) AU2003241161C1 (enExample)
CA (1) CA2487252C (enExample)
CY (2) CY1109581T1 (enExample)
DE (1) DE60328777D1 (enExample)
DK (2) DK1509529T3 (enExample)
ES (2) ES2432379T3 (enExample)
IT (1) ITRM20020306A1 (enExample)
MX (1) MXPA04011681A (enExample)
PE (1) PE20040533A1 (enExample)
PL (1) PL374009A1 (enExample)
PT (2) PT1509529E (enExample)
SI (2) SI2112154T1 (enExample)
TW (1) TWI331151B (enExample)
WO (1) WO2003101996A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN103864811A (zh) * 2012-12-13 2014-06-18 天津科技大学 一种新颖的10-羟基喜树碱20位衍生物制备方法及其在抗肿瘤药物中的应用
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN106279286B (zh) * 2016-08-12 2018-11-30 华中科技大学 一种喜树碱膦酸酯类化合物、其制备方法及应用
CN110577551A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-二溴去甲斑蝥素结合物及其应用
AU2020309244A1 (en) 2019-07-11 2022-03-03 Sun Pharma Advanced Research Company Ltd. Camptothecin derivatives with a disulfide moiety and a piperazine moiety
CN116514828A (zh) * 2020-08-21 2023-08-01 诺茗(北京)生物医药有限公司 一种水溶性抗肿瘤前药及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP3186166B2 (ja) * 1992-02-10 2001-07-11 ロンザ リミテッド サリチロイル−カルニチンおよびその製造方法
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
WO1997021865A1 (en) 1995-12-15 1997-06-19 The Dexter Corporation Abrasive nonwoven web and method of manufacture
DE69923322T2 (de) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
DE19916945C1 (de) 1999-04-15 2000-10-05 Clariant Gmbh Aromatische Aldehydharze und ihre Verwendung als Emulsionsspalter
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6288072B1 (en) 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates

Also Published As

Publication number Publication date
CY1109581T1 (el) 2014-08-13
CN1656101A (zh) 2005-08-17
SI2112154T1 (sl) 2013-12-31
TWI331151B (en) 2010-10-01
PE20040533A1 (es) 2004-08-26
WO2003101996A8 (en) 2004-04-29
ES2331569T3 (es) 2010-01-08
TW200403246A (en) 2004-03-01
PT1509529E (pt) 2009-11-13
ES2432379T3 (es) 2013-12-03
KR20050036910A (ko) 2005-04-20
AR040140A1 (es) 2005-03-16
US20070213353A1 (en) 2007-09-13
AU2003241161B2 (en) 2009-10-22
SI1509529T1 (sl) 2009-12-31
US7498340B2 (en) 2009-03-03
ATE439362T1 (de) 2009-08-15
JP4593270B2 (ja) 2010-12-08
WO2003101996A2 (en) 2003-12-11
JP2005529935A (ja) 2005-10-06
HK1079206A1 (en) 2006-03-31
CA2487252A1 (en) 2003-12-11
DK1509529T3 (da) 2009-12-14
AU2003241161C1 (en) 2010-03-04
ITRM20020306A0 (it) 2002-05-31
EP1509529B1 (en) 2009-08-12
WO2003101996A3 (en) 2004-01-29
ITRM20020306A1 (it) 2003-12-01
MXPA04011681A (es) 2005-03-31
EP1509529A2 (en) 2005-03-02
PL374009A1 (en) 2005-09-19
CA2487252C (en) 2010-08-10
CY1114692T1 (el) 2016-10-05
KR101000963B1 (ko) 2010-12-13
EP2112154B1 (en) 2013-07-24
DK2112154T3 (da) 2013-10-21
PT2112154E (pt) 2013-10-02
EP2112154A1 (en) 2009-10-28
US20050256148A1 (en) 2005-11-17
CN100376583C (zh) 2008-03-26
US7452900B2 (en) 2008-11-18
AU2003241161A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
DE60314378D1 (en) Kristalline polymorphe form von irinotecan-hyrochlorid
GB0203831D0 (en) Flame effect 2
GB0220501D0 (en) Push 22
SI1509529T1 (sl) Estri na poziciji 20 kamptotecina
EP1501722A4 (en) IMPROVEMENTS IN THE BEAUPRES
PL372202A1 (en) Modified byrodin 1 with reduced immunogenicity
GB2388100B (en) "Pallets"
GB0217015D0 (en) Peptide 4
GB0208414D0 (en) The overlock
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
GB0221270D0 (en) Moke 2
GB0206835D0 (en) Iv 2
GB0209835D0 (en) Easy 1
TW435611U (en) Fasteners
GB0116220D0 (en) Improvements in fasteners
GB0114432D0 (en) Improvements in fasteners
GB0212244D0 (en) AM 2000 Sleep-alert
GB0225468D0 (en) Text 4 sale
GB0217018D0 (en) Peptide 1
GB0217017D0 (en) Peptide 2
GB0217014D0 (en) Peptide 3
AU2003900493A0 (en) Improvements in lock - cont 4
AU2003900725A0 (en) Improvements in lock - cont 5
AU2003900103A0 (en) Improvements in lock - Cont 3
GB0219989D0 (en) Carry 3

Legal Events

Date Code Title Description
8364 No opposition during term of opposition